Dick E. De Vries

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Why do healthy volunteers participate in clinical trials?

Why do healthy volunteers participate in clinical trials?

Journal: British journal of clinical pharmacology

Published: July 07, 2025

Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study.

Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study.

Journal: RMD open

Published: August 08, 2024

Prediction of Disease Progression and Clinical Response in Systemic Sclerosis: Experience From a Proof-of-Concept Trial.

Prediction of Disease Progression and Clinical Response in Systemic Sclerosis: Experience From a Proof-of-Concept Trial.

Journal: ACR open rheumatology

Published: December 01, 2023

Impact of filgotinib on pain control in the phase 3 FINCH studies.

Impact of filgotinib on pain control in the phase 3 FINCH studies.

Journal: RMD open

Published: October 23, 2023

Measuring Intracompartmental Pressures in the Lower Leg: Assessing the Use of Unilateral Measurements in Patients with Bilateral Symptoms.

Measuring Intracompartmental Pressures in the Lower Leg: Assessing the Use of Unilateral Measurements in Patients with Bilateral Symptoms.

Journal: JB & JS open access

Published: November 30, 2022

A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis.

A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: June 09, 2022

MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases.

MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases.

Journal: Advances in therapy

Published: January 21, 2022

Data for a city-level health impact assessment of urban transport in Mauritius.

Data for a city-level health impact assessment of urban transport in Mauritius.

Journal: Data in brief

Published: September 07, 2020

Participatory quantitative health impact assessment of urban transport planning: A case study from Eastern Africa.

Participatory quantitative health impact assessment of urban transport planning: A case study from Eastern Africa.

Journal: Environment international

Published: May 25, 2020

Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial.

Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial.

Journal: Annals of the rheumatic diseases

Published: February 05, 2019

Absolute Bioavailability and Pharmacokinetic Comparability of Sirukumab Following Subcutaneous Administration by a Prefilled Syringe or an Autoinjector.

Absolute Bioavailability and Pharmacokinetic Comparability of Sirukumab Following Subcutaneous Administration by a Prefilled Syringe or an Autoinjector.

Journal: Clinical pharmacology in drug development

Published: August 02, 2016

Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach.

Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach.

Journal: Journal of clinical pharmacology

Published: April 15, 2015

Showing 1-12 of 17

Last Updated: 09/26/2026